Skip to content

Diode Laser-Assisted Direct Pulp Capping Trial

Effect of Diode Laser Therapy Following Direct Pulp Capping on Postoperative Pain and Dentin Hypersensitivity: A Randomized Controlled Clinical Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07593508
Enrollment
56
Registered
2026-05-18
Start date
2022-07-01
Completion date
2024-08-31
Last updated
2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Pulp Exposure, Dentin Hypersensitivity, Postoperative Pain

Keywords

Direct pulp capping, Biodentine, Diode laser, Postoperative pain, Dentin hypersensitivity, Vital pulp therapy

Brief summary

This randomized controlled clinical trial evaluates whether adjunctive 808-nm diode laser therapy after direct pulp capping reduces postoperative pain and dentin hypersensitivity compared with conventional Biodentine treatment. Sixty teeth from fifty-six participants with carious pulp exposure were randomly allocated into two treatment groups. Postoperative pain, dentin hypersensitivity, and 6-month clinical success rates were assessed.

Detailed description

Direct pulp capping (DPC) is a vital pulp therapy procedure intended to preserve pulp vitality and stimulate reparative dentin formation after pulp exposure. The clinical success of DPC depends on effective sealing of the exposure site, bacterial control, and maintenance of pulpal health. Bioactive tricalcium silicate-based materials such as Biodentine have demonstrated favorable biological and mechanical properties and are widely used as pulp-capping agents because of their biocompatibility, sealing ability, and dentin-bridge induction potential. Despite the favorable outcomes of modern pulp-capping materials, postoperative pain and dentin hypersensitivity remain common complications following DPC. These symptoms may negatively affect patient comfort, treatment acceptance, and short-term clinical outcomes. Adjunctive use of diode laser therapy has been proposed to improve the biological environment of the exposed pulp by providing hemostasis, antimicrobial action, and photobiomodulation. Experimental and clinical evidence suggests that diode laser irradiation may reduce inflammation, stabilize cell membranes, improve microcirculation, and enhance cellular metabolism through increased adenosine triphosphate (ATP) synthesis, thereby reducing postoperative discomfort and promoting tissue healing. However, evidence regarding the effectiveness of diode laser therapy as an adjunct to DPC remains limited, particularly due to variations in laser parameters, treatment protocols, and pulp-capping materials among previous studies. Therefore, this randomized controlled clinical trial was designed to evaluate the clinical effectiveness of adjunctive 808-nm diode laser therapy following direct pulp capping using Biodentine. A total of 60 teeth from 56 participants diagnosed with carious pulp exposure and fulfilling the eligibility criteria were included. Eligible teeth were randomly allocated into two groups using a computer-generated 1:1 randomization sequence with allocation concealment by sequentially numbered, opaque, sealed envelopes (SNOSE). In the control group, direct pulp capping was performed using Biodentine following conventional hemostasis and disinfection procedures. In the experimental group, adjunctive diode laser therapy (808 nm) was applied for hemostasis and disinfection prior to Biodentine placement, using standardized irradiation parameters. The primary outcomes of the study are postoperative pain intensity and dentin hypersensitivity. Postoperative pain is assessed using the Numerical Rating Scale (NRS, 0-10) and the duration until complete pain resolution is recorded. Dentin hypersensitivity is evaluated at 1, 3, and 6 months using a cold stimulus and NRS scoring. The secondary outcome is the clinical success rate at 6 months, determined by clinical and radiographic criteria including pulp vitality, absence of spontaneous pain, absence of tenderness to percussion, and absence of radiographic periapical pathology. The study hypothesizes that adjunctive diode laser therapy will significantly reduce postoperative pain and dentin hypersensitivity following direct pulp capping compared with conventional Biodentine treatment, while maintaining comparable clinical success rates at 6 months.

Interventions

DEVICEBiodentine

Biodentine was used as a bioactive tricalcium silicate pulp-capping material placed directly over the exposed pulp tissue following hemostasis and cavity disinfection.

DEVICE808-nm Diode Laser

Adjunctive diode laser irradiation was applied for hemostasis and disinfection before Biodentine placement during direct pulp capping.

Sponsors

Hue University of Medicine and Pharmacy
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Due to the nature of the intervention, blinding of participants and care providers was not feasible because diode laser application was visible and audible during treatment. However, the outcome assessor responsible for evaluating postoperative pain, dentin hypersensitivity, and clinical follow-up outcomes was blinded to group allocation throughout the study. All assessment forms were coded by participant ID without treatment information, and participants were instructed not to disclose their treatment assignment during follow-up visits.

Intervention model description

This is a randomized, parallel-group clinical trial in which eligible teeth with carious pulp exposure were allocated in a 1:1 ratio to either conventional direct pulp capping with Biodentine (control group) or diode laser-assisted direct pulp capping with Biodentine (experimental group). Randomization was performed at the tooth level using a computer-generated sequence with allocation concealment by sequentially numbered, opaque, sealed envelopes (SNOSE). Clinical outcomes were evaluated at predefined follow-up intervals by a blinded outcome assessor.

Eligibility

Sex/Gender
ALL
Age
10 Years to 58 Years
Healthy volunteers
No

Inclusion criteria

* Participants aged 10 to 58 years. * Teeth with pulp exposure caused by caries removal. * Vital teeth confirmed by clinical pulp vitality tests (cold and heat tests) and radiographic examination. * No history of spontaneous pain; only mild or tolerable discomfort to cold stimuli. * Pulp exposure less than 2 mm in diameter. * Normal radiographic findings with no periapical pathology. * Bleeding controllable within 10 minutes. * Written informed consent obtained from participants or legal guardians.

Exclusion criteria

* Pulp exposure caused by trauma or occlusal wear. * Teeth unsuitable for restoration, including subgingival fractures or vertical root cracks. * Clinical signs of irreversible pulpitis, abscess, or sinus tract. * Uncontrollable bleeding after 10 minutes of saline pressure or laser hemostasis. * Previous use of analgesics before treatment. * Multiple pulp exposures in the same dental arch.

Design outcomes

Primary

MeasureTime frameDescription
Dentin Hypersensitivity1 month, 3 months, and 6 months after treatmentDentin hypersensitivity will be assessed using a cold stimulus test (0-4°C water) and recorded using the Numerical Rating Scale (NRS, 0-10), where higher scores indicate greater sensitivity.
Postoperative Pain IntensityDaily until complete pain resolution (up to 7 days after treatment)Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS, 0-10), where 0 indicates no pain and 10 indicates the worst pain imaginable. Participants will record daily pain scores until complete pain resolution.

Secondary

MeasureTime frameDescription
Clinical Success Rate6 months after treatmentClinical success will be evaluated based on pulp vitality, absence of spontaneous pain, absence of tenderness to percussion, absence of pathological mobility, and absence of radiographic periapical pathology.

Countries

Vietnam

Contacts

PRINCIPAL_INVESTIGATORAnh Chi PHAN, PhD

Hue University of Medicine and Pharmacy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 19, 2026